September 2017
Volume 3, Issue 11
This issue features a look at efforts to include individuals with intellectual and developmental disabilities in clinical research, our new “How I Treat In Brief” section, and more.
Table of Contents
September 2017 Issue
Is This Case of Deep Vein Thrombosis Provoked or Unprovoked?
Here’s how readers responded to a You Make the Call question about travel-related deep vein thrombosis.
Disclaimer: ASH does not recommend or endorse any specific...
Meaningful Benefits
Two roads diverged in a wood, and I –
I took the one less traveled by,
And that has made all the difference.
Robert Frost, “The Road...
Pulling Back the Curtain: Gerald A. Soff, MD
In this edition, Gerald A. Soff, MD, shares his experiences as a hematologist and a hematologic patient, and he discusses how his myeloma diagnosis...
History-omics
As hematologists, we are privileged to work at the forefront of the molecular age of medicine. Diagnostic, prognostic, and predictive genomic information has been...
September 2017 Issue
New CDC Director Named, NIH Awards Grants for Cancer Cell Metastases, and more
Brenda Fitzgerald Named New Director of the Centers for Disease Control and Prevention
Brenda Fitzgerald, MD, the Georgia Public Health Commissioner, has been appointed director...
2017 ASH Clinical Research Training Institute Participants, AML Matters Summit, and more
Fellows and Junior Faculty Selected for 2017 ASH Clinical Research Training Institute
Twenty hematology and hematology/oncology fellows and junior faculty will participate in the 2017...
September 2017 Issue
Rewriting the Rules of Informed Consent
A look at efforts to include individuals with intellectual and developmental disabilities in clinical research
When hematologist/oncologist Cecilia Arana Yi, MD, first saw George (name...
B.Y.O.B. (Build Your Own Boat): Joseph Antin, MD
In this edition of pASHions, Joseph H. Antin, MD, discusses his lifelong interest in boats – from reading about adventures at sea when he...
September 2017 Issue
Is this case of deep vein thrombosis provoked or unprovoked?
This month Beth Battinelli, MD, PhD, discusses thrombosis development after extended travel.
And don’t forget to check out next month’s clinical dilemma – send in your responses for...
How I Treat In Brief: Atypical Chronic Myeloid Leukemia
This month, Jason Gotlib, MD, discusses the diagnosis and treatment of patients with atypical chronic myeloid leukemia.
This material was repurposed from “How I Treat...
September 2017 Issue
Number of Older Patients Receiving AlloHCT Increased Over the Past Decade
Historically, older adults have not been considered optimal candidates for hematopoietic cell transplantation (HCT) because of concerns about transplant-related toxicity and mortality. Over the...
Examining Nilotinib to Prevent Post-Transplant Relapse in Patients With Ph+ Leukemia
In previous research published in Blood, Paul A. Carpenter, MBBS, from the Fred Hutchinson Cancer Research Center in Seattle, Washington, and co-authors determined that...
Trial Roundup: PRTX-100 for Immune Thrombocytopenia, APR-246 for Myeloid Neoplasms, and more
ASH Clinical News' Associate Editors select clinical trials to keep an eye on in leukemia, bleeding disorders, and lymphoma & myeloma.David Steensma, MD
Dana-Farber Cancer Institute
A...
Examining Vorinostat to Prevent Graft-Versus-Host Disease After Unrelated Donor HCT
While the histone deacetylase (HDAC) inhibitor vorinostat led to a low incidence of acute graft-versus-host disease (GVHD) following hematopoietic cell transplantation (HCT) with reduced-intensity...
Ruxolitinib Versus Best Available Therapy for Essential Thrombocythemia
Treatment with the JAK1/2 inhibitor ruxolitinib failed to improve response rates, compared with best-available therapy (BAT) in patients with essential thrombocythemia (ET) who were...
Investigating How Patients With Hemophilia Manage Pain
As the life expectancy of people with hemophilia has increased, patients are living longer with disease-associated pain, particularly in their joints. According to the...
Is Idarucizumab the First “Antidote” to a Direct Oral Anticoagulant?
Idarucizumab “rapidly and completely” reversed the blood-thinning effects of the direct oral anticoagulant dabigatran in patients who had uncontrolled bleeding or were about to...
Can Gilteritinib Overcome FLT3 Inhibition Resistance in Patients With FLT3-Mutated AML?
Treatment with the oral FLT3/AXL inhibitor gilteritinib showed consistent FLT3 inhibition and high response rates in patients with FLT3-mutated, relapsed or refractory acute myeloid...
Venetoclax Gets Breakthrough-Therapy Designation for AML
The FDA granted breakthrough-therapy designation to the BCL2 inhibitor venetoclax, in combination with cytarabine, for the treatment of older patients with treatment-naïve AML who...
Researchers Carry Out First Gene Editing of Embryos in the United States
A team of researchers at Oregon Health and Science University successfully used gene-editing technology to correct defective genes in a human embryo. This is...
President Declares State of Emergency After Urged by Federal Opioid Commission
On August 10, President Trump declared the opioid crisis a national emergency in response to a report from the Commission on Combating Drug Addiction...
FDA Approves First New Sickle Cell Therapy in Nearly 20 Years
The U.S. Food and Drug Administration approved L-glutamine oral powder for patients ≥5 years old with sickle cell disease (SCD). It is the first...
Eculizumab Associated With Increased Risk of Meningococcal Disease
A report from the Centers for Disease Control and Prevention (CDC) noted that eculizumab – a drug approved by the U.S. Food and Drug...
Can Reduced-Dose Rituximab Effectively Prevent TTP Recurrence?
Previous research suggests that the anti-CD20 monoclonal antibody rituximab, at a dose of 375 mg/m2, can prevent relapse in patients with thrombotic thrombocytopenic purpura...
FDA Approves Combination Daunorubicin and Cytarabine for High-Risk AML
The U.S. Food and Drug Administration approved CPX-351, a fixed combination of cytarabine and daunorubicin, for the treatment of adults with newly diagnosed therapy-related...
September 2017
Emicizumab Significantly Decreases Bleeding Rate, Compared With No Treatment in Patients With Hemophilia A
In the phase III HAVEN-1 study, preventive treatment with emicizumab significantly reduced bleeding rates, compared with no treatment in patients with hemophilia A with...
RNA Interference Therapy Fitusiran Improves Thrombin Generation in Patients With Hemophilia
The investigational RNA interference therapy fitusiran lowered levels of antithrombin in patients with hemophilia A or B with or without inhibitors, leading to improved...
